Last updated: February 22, 2026
Case Overview
Endo Pharmaceuticals Inc. filed a patent infringement lawsuit against IMPAX Laboratories, Inc., in the U.S. District Court for the District of Delaware. The case number is 1:13-cv-00435, initiated on March 1, 2013. Endo alleged that IMPAX’s generic versions of certain opioid products infringed upon Endo's patents related to extended-release formulations.
Patent Portfolio and Allegations
Endo’s claims focused primarily on U.S. Patent Nos. 7,973,990 and 8,330,223. These patents claim methods of making controlled-release opioid formulations with specific release profiles and methods of use.
Key assertions by Endo include:
- The patent claims cover the composition and manufacturing methods used in IMPAX’s generic drug products.
- IMPAX's manufacturing process infringes these patents by producing extended-release formulations with similar release characteristics.
- The infringement impacts Endo’s market exclusivity and potential revenue streams for its branded products, such as OPANA ER.
Procedural History and Court Proceedings
Filing and Initial Motions
Endo filed the complaint on March 1, 2013. IMPAX responded with a motion to dismiss, challenging the validity of the patents under 35 U.S.C. § 101 (patent eligibility) and other grounds.
Patent Validity and Summary Judgment Motions
Both parties engaged in motions for summary judgment, focusing on:
- Patent validity, including novelty and non-obviousness.
- Non-infringement, based on differences in manufacturing processes and formulation properties.
- Patent enforceability, considering potential previous disclosures.
Settlement and Resolution
The case did not proceed to trial. On December 13, 2013, the parties reached a settlement agreement. The terms included:
- IMPAX’s license to the patents.
- A stipulated dismissal of the case with prejudice.
- Confidentiality clauses and financial terms unspecified in publicly available court filings.
Patent Litigation Trends Context
This case reflects common patent enforcement strategies among pharmaceutical companies, particularly in extending market exclusivity or defending against generic entry. It aligns with the broader trend of patent litigation in the opioid and controlled-release drug segments, which have witnessed numerous patent disputes aimed at delaying generic competition.
Analysis
Strategic Implications
Endo’s litigation aimed to protect exclusivity of its patented extended-release formulations, critical due to the high market value of opioids like OPANA ER. The settlement indicates the potential for licensing arrangements over contested patents, avoiding lengthy trials and uncertain outcomes.
Patent Strengths and Vulnerabilities
The patents’ focus on specific formulation characteristics and manufacturing methods provided a basis for infringement claims. However, the validity risks based on prior art and obviousness were common defenses in similar cases.
Market Impact
The resolution allowed IMPAX to produce generic opioids with certain licensing terms, likely enabling market entry sooner than through prolonged litigation. The case underscores the importance of patent fortification and strategic litigation to secure market share.
Key Data Points
| Aspect |
Details |
| Case Number |
1:13-cv-00435 |
| Court |
U.S. District Court, District of Delaware |
| Litigation Start Date |
March 1, 2013 |
| Patents Involved |
U.S. Patent Nos. 7,973,990 and 8,330,223 |
| Claims Focus |
Extended-release formulation methods and properties |
| Outcome |
Settlement and license agreement |
| Duration of Litigation |
Approximately 9 months |
Key Takeaways
- The case exemplifies patent enforcement efforts to defend formulations of high-value opioids.
- Settlement indicates a preference for licensing over protracted litigation.
- Patent claims targeted manufacturing processes and formulation characteristics, common in controlling extended-release drug markets.
- The outcome facilitated later generic market entry for IMPAX under licensing terms, minimizing market disturbance.
- Litigation trends reflect strategic patent use against generics, shaping market dynamics in high-stakes segments like opioids.
FAQs
1. Did the case set a precedent for patent validity issues in extended-release formulations?
No, the case primarily concluded with a settlement, but it reflects ongoing patent validity challenges, especially concerning obviousness and prior art.
2. How could patent weaknesses affect future litigation?
Weaknesses in prior art disclosing similar formulations can render patents vulnerable to invalidity claims, affecting enforcement efforts.
3. What role does licensing play in resolving patent disputes?
Licensing provides an alternative to litigation, allowing market access while generating revenue through patent rights.
4. Are such patent disputes common in the opioid market?
Yes, patent disputes are prevalent due to high market value and the strategic importance of market exclusivity.
5. What is the significance of settlement agreements in patent cases?
Settlements enable the parties to avoid uncertainty and expense associated with trial, often resulting in licensing agreements or injunctions.
References
[1] U.S. District Court for the District of Delaware. (2013). Endo Pharmaceuticals Inc. v. IMPAX Laboratories, Inc., Case No. 1:13-cv-00435.
